Cristina Gasparetto

Dr. Gasparetto performs both laboratory and clinical research in the field of multiple myeloma. Her primary research interests are in developing immunotherapy approaches to treating multiple myeloma particularly in conjunction with hematopoietic stem cell transplantation. Ongoing laboratory research projects include the development of dendritic cell vaccines and antibody therapies. Clinical studies include a recently approved trial involving vaccination with autologous dendritic cells pulsed with idiotypic protein following high dose chemotherapy and autologous peripheral blood stem cells transplant. Upcoming trials include novel antibody therapies for multiple myeloma. Dr. Gasparetto is also an investigator on several other clinical trials for myeloma including non-myeloablative allogeneic transplantation, high dose sequential chemotherapy and autologous peripheral blood stem cell transplantation and transplantation of partially HLA matched unrelated cord blood.

Current Appointments & Affiliations

Professor of Medicine · 2018 - Present Medicine, Hematologic Malignancies and Cellular Therapy, Medicine

Member of the Duke Cancer Institute · 1993 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications

Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study.

Journal Article Lancet Haematol · June 27, 2025 BACKGROUND: The phase 3 BELLINI primary endpoint was met, showing superior progression-free survival with venetoclax versus placebo plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma as assessed by an independent rev ... Full text Link to item Cite

Food insecurity prior to hematopoietic stem cell transplant is associated with malnutrition and worse outcomes.

Journal Article Bone Marrow Transplant · June 2025 Food insecurity (FI), defined as the lack of continuous access to adequate food, affects 17-55% of cancer patients. Effects may be exacerbated in hematopoietic stem cell transplant (HSCT) patients, who face nutritional challenges due to treatment side effe ... Full text Link to item Cite

Treatment Patterns, Efficacy, and Tolerability of Belantamab Mafodotin in Patients With Relapsed and/or Refractory Multiple Myeloma: A Real-World Analysis.

Journal Article Clin Lymphoma Myeloma Leuk · April 15, 2025 PURPOSE: Belantamab mafodotin is an anti-B cell maturation antigen (BCMA) immunoconjugate for patients with relapsed/refractory multiple myeloma (RRMM). Additional data on its treatment patterns, efficacy, and tolerability in real-world settings are needed ... Full text Link to item Cite

View All Publications

Recent Grants

Celgene: CA057-001 - A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480, BORTEZOMIB AND DEXAMETHASONE (480Vd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYE

Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2024 - 2029

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma

Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2024 - 2029

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)

Clinical TrialPrincipal Investigator · Awarded by Caribou Biosciences, Inc. · 2023 - 2028

View All Grants

Education, Training & Certifications

Sapienza University of Rome (Italy) · 1986 M.D.